Is BostonGene profitable in 2026?

BostonGene has not disclosed audited revenue or profitability figures. Third party estimates are unconfirmed and inconsistent, ranging widely. The company last raised $150M in a Series B round closing April 6, 2022 at a valuation over $1B, but no profitability data has been published since.

BostonGene is privately held. NEC Corporation led both its Series A ($50M, April 2019) and Series B ($150M, April 6, 2022, unicorn valuation over $1B) rounds, alongside Impact Investment Capital and Japan Industrial Partners. Founders reportedly retain majority equity as of 2026.

Could AI replace BostonGene's diagnostics business?

Unlikely soon. BostonGene runs a CLIA certified, CAP accredited clinical lab as confirmed May 5, 2026, a regulatory and liability bar that generic frontier AI models cannot casually assume. Its moat is regulation and proprietary multi omic pharma data, not something a chatbot can replicate.

Who is BostonGene's biggest competitor?

Tempus AI, Caris Life Sciences and Guardant Health are BostonGene's closest rivals in precision oncology AI diagnostics. Caris posted 79% YoY revenue growth to $216M in Q1 2026, and Guardant grew 48% YoY to $301.7M, both far outpacing BostonGene's undisclosed scale.

Is BostonGene planning an IPO?

No formal IPO process has been announced as of July 2026. Forge Global lists BostonGene as available to accredited pre IPO investors on secondary markets, and speculation about an eventual IPO or acquisition exists, but the company has made no public announcement of listing plans.

Has BostonGene had layoffs?

No layoffs, lawsuits or regulatory actions were found reported as of July 2026. Headcount estimates vary widely across data providers, from 160 to 360 employees, but no source indicates workforce reductions.

United States · United States

BostonGene

Clinical-grade multi-omic profiling platform for precision oncology, used by pharma and doctors.

Losing its protection

Assessed 29 July 2026 · Evidence as of 29 July 2026

The structural protection is eroding.

On the recordSince 29 July 2026 · Checkable from Q4 2026 · Every call on the record Checkpoint: Tempus AI and Caris Life Sciences Q4 earnings and next BostonGene pharma partnership disclosure

The call

BostonGene holds a certified clinical niche that AI models can't easily copy, but larger, faster-growing precision-oncology rivals are pulling ahead in the same market.

BostonGene uses blood tests and AI to help doctors pick the right cancer drugs for patients. It has built real defenses, like clinical lab licenses and years of patient data that are hard to copy, plus deals with drug makers like AstraZeneca that keep customers locked in. But this does not protect it from competitors like Tempus and Caris, which are 5 to 15 times larger, growing much faster, and already winning the same customers in the same cancer-diagnostics market. The one thing that could change this is if BostonGene lands a major new partnership or gets bought by a larger company before its rivals lock up all the market share.

Why

AI pressure: Generalist AI diagnostics models from labs like Roche/Foundation Medicine or Tempus AI. Big players are building their own AI oncology models, but CLIA/CAP lab certification blocks a quick copy of BostonGene's clinical workflow. Could AI do the core job? Unlikely.

Bigger players: Tempus AI, Caris Life Sciences, Guardant Health. These rivals run live precision-oncology platforms in the same market, are 5 to 15 times larger, and growing 50 to 80% a year. Could a giant copy it? Probably.

What protects it. CLIA/CAP-certified clinical lab plus proprietary multi-omic patient data and locked-in pharma workflows with AstraZeneca, J&J, Takeda.

What would change this call

Tempus AI or Caris Life Sciences report Q3/Q4 2026 YoY growth above 50%. Confirms larger rivals are outpacing BostonGene and likely absorbing shared pharma and hospital accounts.
BostonGene discloses independent revenue or ARR figures publicly. Would clarify whether BostonGene's growth keeps pace with larger rivals or is falling behind.
NEC Corporation announces a stake increase or take-private move for BostonGene. Would show NEC shoring up BostonGene's capital position against larger, better-funded competitors.

Key numbers

$120M Series B-2 at $1.46B post-money valuation (2024-12)
~$320M total funding raised to date (2026-06-30)
AstraZeneca cancer-drug collaboration announced (2026-01-06)

Named risks

Sub-scale versus faster growing, better capitalized public rivals chasing the same pharma deals. Severity: high
Revenue undisclosed by company, third party estimates conflict and are unverified. Severity: medium
Deal terms with major partners like AstraZeneca remain undisclosed, obscuring real commercial traction. Severity: medium
Headcount estimates vary from 160 to 360 employees across data providers, signaling data opacity. Severity: low

Rivals, as read in July 2026

Rival	Direction	Evidence
Tempus AI	gaining on	Reported ~$348M quarterly revenue in Q1 2026 versus BostonGene's undisclosed revenue
Caris Life Sciences	gaining on	Grew revenue 79% YoY to $216M in Q1 2026, same pharma partnership market as BostonGene
Guardant Health	gaining on	Grew revenue 48% YoY to $301.7M in Q1 2026, raised FY2026 guidance to $1.30-1.32B
Foundation Medicine (Roche)	contesting	Established DNA based tumor genomic testing pioneer, named top BostonGene alternative

Questions people ask

Is BostonGene profitable in 2026?: BostonGene has not disclosed audited revenue or profitability figures. Third party estimates are unconfirmed and inconsistent, ranging widely. The company last raised $150M in a Series B round closing April 6, 2022 at a valuation over $1B, but no profitability data has been published since.
Who owns BostonGene?: BostonGene is privately held. NEC Corporation led both its Series A ($50M, April 2019) and Series B ($150M, April 6, 2022, unicorn valuation over $1B) rounds, alongside Impact Investment Capital and Japan Industrial Partners. Founders reportedly retain majority equity as of 2026.
Could AI replace BostonGene's diagnostics business?: Unlikely soon. BostonGene runs a CLIA certified, CAP accredited clinical lab as confirmed May 5, 2026, a regulatory and liability bar that generic frontier AI models cannot casually assume. Its moat is regulation and proprietary multi omic pharma data, not something a chatbot can replicate.
Who is BostonGene's biggest competitor?: Tempus AI, Caris Life Sciences and Guardant Health are BostonGene's closest rivals in precision oncology AI diagnostics. Caris posted 79% YoY revenue growth to $216M in Q1 2026, and Guardant grew 48% YoY to $301.7M, both far outpacing BostonGene's undisclosed scale.
Is BostonGene planning an IPO?: No formal IPO process has been announced as of July 2026. Forge Global lists BostonGene as available to accredited pre IPO investors on secondary markets, and speculation about an eventual IPO or acquisition exists, but the company has made no public announcement of listing plans.
Has BostonGene had layoffs?: No layoffs, lawsuits or regulatory actions were found reported as of July 2026. Headcount estimates vary widely across data providers, from 160 to 360 employees, but no source indicates workforce reductions.

Timeline

2026-07-22BostonGene and Kyoto University announce strategic partnership for GI cancer trial
2026-07-07BostonGene named Overall AI-based Analytics Company of the Year in AI Breakthrough Awards
2026-05-11Hokkaido University collaboration expanded to cover 20+ cancer types
2026-05-05BostonGene receives Frost and Sullivan 2026 Global Company of the Year recognition
2026-04BostonGene presents 13 abstracts at AACR Annual Meeting on AI drug development platform
2026-01-06BostonGene and AstraZeneca announce strategic oncology collaboration
2024-03-05Transgene, NEC and BostonGene expand neoantigen vaccine trial collaboration
2022-04-06BostonGene closes $150M Series B led by NEC, reaches unicorn valuation over $1B
2019-04BostonGene closes $50M Series A led by NEC Corporation
2015BostonGene founded

Revision history

29 July 2026

First assessed. Losing its protection. The text above is fixed as of this date and is not edited afterwards.

In the same band

American Airlines Group Wayfair Safe Superintelligence Inc.